Gilead Sciences (NASDAQ:GILD) Price Target Raised to $155.00

Gilead Sciences (NASDAQ:GILD) had its price target upped by research analysts at UBS Group from $145.00 to $155.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. UBS Group’s price objective would indicate a potential upside of 12.32% from the company’s previous close.

A number of other equities research analysts have also recently issued reports on the company. Needham & Company LLC boosted their price objective on Gilead Sciences from $133.00 to $140.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Morgan Stanley cut their price objective on shares of Gilead Sciences from $151.00 to $150.00 and set an “overweight” rating for the company in a report on Tuesday, January 13th. Daiwa Capital Markets boosted their target price on shares of Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a report on Thursday, November 13th. Rothschild & Co Redburn raised their price target on Gilead Sciences from $153.00 to $159.00 and gave the stock a “buy” rating in a report on Tuesday, January 20th. Finally, The Goldman Sachs Group boosted their price objective on Gilead Sciences from $110.00 to $115.00 and gave the company a “neutral” rating in a research note on Thursday, January 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $134.52.

Gilead Sciences Stock Performance

Shares of GILD traded up $2.07 on Monday, reaching $138.00. 4,102,575 shares of the company’s stock traded hands, compared to its average volume of 7,152,059. The stock’s 50 day simple moving average is $123.98 and its two-hundred day simple moving average is $118.71. The stock has a market cap of $171.21 billion, a PE ratio of 21.39, a PEG ratio of 0.71 and a beta of 0.33. Gilead Sciences has a 52-week low of $93.10 and a 52-week high of $137.99. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping the consensus estimate of $2.16 by $0.31. The business had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business’s revenue was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, analysts forecast that Gilead Sciences will post 7.95 earnings per share for the current fiscal year.

Insider Activity at Gilead Sciences

In related news, Director Kelly A. Kramer sold 2,805 shares of the company’s stock in a transaction on Friday, November 28th. The shares were sold at an average price of $127.10, for a total value of $356,515.50. Following the completion of the transaction, the director directly owned 1,339 shares in the company, valued at approximately $170,186.90. The trade was a 67.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total value of $617,500.00. Following the sale, the director owned 8,920 shares in the company, valued at $1,101,620. The trade was a 35.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 141,757 shares of company stock worth $17,569,112 in the last three months. 0.27% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Csenge Advisory Group boosted its position in shares of Gilead Sciences by 319.0% in the third quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company’s stock worth $2,375,000 after purchasing an additional 16,288 shares during the period. Railway Pension Investments Ltd boosted its holdings in Gilead Sciences by 3.1% in the 3rd quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company’s stock worth $157,139,000 after buying an additional 42,200 shares during the period. TriaGen Wealth Management LLC purchased a new stake in Gilead Sciences in the 3rd quarter worth $1,274,000. Invesco Ltd. lifted its position in shares of Gilead Sciences by 33.5% in the second quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after acquiring an additional 3,394,330 shares in the last quarter. Finally, iA Global Asset Management Inc. grew its position in shares of Gilead Sciences by 11.6% during the third quarter. iA Global Asset Management Inc. now owns 221,890 shares of the biopharmaceutical company’s stock worth $24,630,000 after purchasing an additional 23,046 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.